MX2019001780A - Composicion de vacuna multivalente novedosa. - Google Patents
Composicion de vacuna multivalente novedosa.Info
- Publication number
- MX2019001780A MX2019001780A MX2019001780A MX2019001780A MX2019001780A MX 2019001780 A MX2019001780 A MX 2019001780A MX 2019001780 A MX2019001780 A MX 2019001780A MX 2019001780 A MX2019001780 A MX 2019001780A MX 2019001780 A MX2019001780 A MX 2019001780A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- ipv
- aluminum hydroxide
- rotavirus
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una vacuna o vacunas de combinación inmunogénica estables que comprenden una mezcla de antígenos para la prevención y profilaxis de infecciones causadas por el rotavirus, el virus de la poliomielitis, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis y el virus de la Hepatitis B. La invención proporciona en particular una vacuna de combinación multivalente que comprende: i) antígenos de IPV Salk o IPV Sabin (IPV) en dosis significativamente reducida, preparados mediante el uso de métodos mejorados de inactivación de formaldehído y adsorción de hidróxido de aluminio, que dan como resultado la recuperación máxima del antígeno D y ii) Antígeno (s) de rotavirus inactivado por calor e inyectable obtenido de cepas de rotavirus (CDC-9) que proporcionan una amplia inmunidad de protección cruzada entre las cepas de rotavirus humano, iii) conjugado de PRP de Hib-proteína transportadora que tiene estabilidad e inmunogenicidad mejoradas en donde el conjugado de PRP Hib-proteína transportadora es inicialmente preparado usando un nuevo proceso de conjugación y posteriormente se mezcla a baja temperatura en presencia de un estabilizador para minimizar la liberación de PRP libre, iv) antígeno de pertussis de células completas con inmunogenicidad y estabilidad mejoradas obtenidas mediante la adición de antígeno de pertussis de células enteras en una etapa posterior en una mezcla, minimizando así la degradación basada en hidrólisis v) fracciones homogéneas de toxoide de difteria y toxoide tetánico obtenidos mediante la eliminación de agregados no deseados por el uso de cromatografía por permeación en gel. También se describe el proceso para producir estas composiciones de vacunas inmunogénicas estables mediante las etapas de i) adsorber individualmente IPV en dosis reducida, antígenos de IRV en el hidróxido de aluminio, manteniendo el otro antígeno (s) no absorbido o adsorbido en fosfato de aluminio, hidróxido de aluminio, en una combinación de hidróxido de aluminio y fosfato de aluminio y ii) usar un orden particular de adición de antígenos durante la mezcla.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621029037 | 2016-08-26 | ||
| PCT/IB2017/055100 WO2018037365A1 (en) | 2016-08-26 | 2017-08-24 | Multivalent vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001780A true MX2019001780A (es) | 2020-01-13 |
Family
ID=60083359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001780A MX2019001780A (es) | 2016-08-26 | 2017-08-24 | Composicion de vacuna multivalente novedosa. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11235054B2 (es) |
| EP (1) | EP3503917B1 (es) |
| JP (3) | JP7384667B2 (es) |
| KR (1) | KR102607295B1 (es) |
| CN (1) | CN110691611A (es) |
| AU (1) | AU2017316768B2 (es) |
| CA (1) | CA3032901A1 (es) |
| CU (1) | CU24682B1 (es) |
| EA (1) | EA201900117A1 (es) |
| IL (1) | IL264605B2 (es) |
| MX (1) | MX2019001780A (es) |
| MY (1) | MY191163A (es) |
| NZ (1) | NZ751127A (es) |
| PE (1) | PE20200004A1 (es) |
| PH (1) | PH12019500404B1 (es) |
| SG (1) | SG11201900365WA (es) |
| UA (1) | UA129115C2 (es) |
| WO (1) | WO2018037365A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12019500404B1 (en) * | 2016-08-26 | 2024-05-15 | Serum Institute Of India Pvt Ltd | Multivalent vaccine composition |
| WO2018208547A1 (en) * | 2017-05-10 | 2018-11-15 | University Of Massachusetts | Bivalent dengue/hepatitis b vaccines |
| JOP20190242A1 (ar) * | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175456A1 (en) * | 2005-04-18 | 2011-11-28 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
| HRP20120557T1 (hr) * | 2006-09-07 | 2012-07-31 | GlaxoSmithKline@Biologicals@s@a | Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| ES2723776T3 (es) * | 2009-05-12 | 2019-09-02 | The Government Of The Us Secretary Department Of Health And Human Services | Nuevas cepas de rotavirus humano y vacunas |
| CN103442730B (zh) * | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
| WO2012117377A1 (en) * | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| SG11201702838SA (en) * | 2014-10-07 | 2017-05-30 | Serum Inst Of India Private Ltd | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
| PH12019500404B1 (en) * | 2016-08-26 | 2024-05-15 | Serum Institute Of India Pvt Ltd | Multivalent vaccine composition |
-
2017
- 2017-08-24 PH PH1/2019/500404A patent/PH12019500404B1/en unknown
- 2017-08-24 SG SG11201900365WA patent/SG11201900365WA/en unknown
- 2017-08-24 CU CU2019000013A patent/CU24682B1/es unknown
- 2017-08-24 MY MYPI2019001011A patent/MY191163A/en unknown
- 2017-08-24 AU AU2017316768A patent/AU2017316768B2/en active Active
- 2017-08-24 EP EP17783992.5A patent/EP3503917B1/en active Active
- 2017-08-24 NZ NZ751127A patent/NZ751127A/en unknown
- 2017-08-24 PE PE2019000409A patent/PE20200004A1/es unknown
- 2017-08-24 WO PCT/IB2017/055100 patent/WO2018037365A1/en not_active Ceased
- 2017-08-24 MX MX2019001780A patent/MX2019001780A/es unknown
- 2017-08-24 JP JP2019532214A patent/JP7384667B2/ja active Active
- 2017-08-24 CN CN201780052380.5A patent/CN110691611A/zh active Pending
- 2017-08-24 KR KR1020197008377A patent/KR102607295B1/ko active Active
- 2017-08-24 EA EA201900117A patent/EA201900117A1/ru unknown
- 2017-08-24 CA CA3032901A patent/CA3032901A1/en active Pending
- 2017-08-24 US US16/327,513 patent/US11235054B2/en active Active
- 2017-08-24 UA UAA201902890A patent/UA129115C2/uk unknown
- 2017-08-24 IL IL264605A patent/IL264605B2/en unknown
-
2021
- 2021-07-16 JP JP2021118038A patent/JP2021181445A/ja active Pending
-
2023
- 2023-10-06 JP JP2023174503A patent/JP2024009899A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017316768A1 (en) | 2019-04-11 |
| PH12019500404B1 (en) | 2024-05-15 |
| CA3032901A1 (en) | 2018-03-01 |
| MY191163A (en) | 2022-06-03 |
| CU24682B1 (es) | 2023-10-06 |
| WO2018037365A1 (en) | 2018-03-01 |
| AU2017316768B2 (en) | 2024-04-11 |
| IL264605B (en) | 2022-12-01 |
| JP2024009899A (ja) | 2024-01-23 |
| JP2021181445A (ja) | 2021-11-25 |
| EP3503917B1 (en) | 2024-07-03 |
| UA129115C2 (uk) | 2025-01-22 |
| BR112019003419A2 (pt) | 2019-05-21 |
| EA201900117A1 (ru) | 2019-09-30 |
| US20190175722A1 (en) | 2019-06-13 |
| KR20190142311A (ko) | 2019-12-26 |
| NZ751127A (en) | 2025-08-29 |
| JP2019526635A (ja) | 2019-09-19 |
| US11235054B2 (en) | 2022-02-01 |
| PE20200004A1 (es) | 2020-01-06 |
| JP7384667B2 (ja) | 2023-11-21 |
| IL264605A (en) | 2019-02-28 |
| PH12019500404A1 (en) | 2020-01-20 |
| EP3503917A1 (en) | 2019-07-03 |
| IL264605B2 (en) | 2023-04-01 |
| SG11201900365WA (en) | 2019-02-27 |
| WO2018037365A8 (en) | 2018-09-20 |
| CN110691611A (zh) | 2020-01-14 |
| CU20190013A7 (es) | 2019-10-04 |
| KR102607295B1 (ko) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100366A1 (es) | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion | |
| JOP20180069B1 (ar) | تركيبة مولدة للمناعة لها ثبات محسن، توليد مناعي معزز وتوليد قدرة تفاعلية منخفض، وعملية لتحضيرها | |
| MX2019001780A (es) | Composicion de vacuna multivalente novedosa. | |
| BR112013017171A2 (pt) | vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos | |
| AR092896A1 (es) | Composiciones inmunogenicas | |
| JP7063957B2 (ja) | エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物 | |
| BRPI0810778A2 (pt) | kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo | |
| PE20211648A1 (es) | Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma | |
| JP2015531389A5 (es) | ||
| CO6430435A2 (es) | Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas | |
| Odutola et al. | Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines–a phase II, randomised, observer-blind study in Gambian infants | |
| AR118407A1 (es) | Composición de vacuna multivalente | |
| RU2015111987A (ru) | Несшитые бесклеточные коклюшные антигены для применения в комбинированных вакцинах | |
| AR117191A1 (es) | Composiciones inmunogénicas | |
| AR101256A1 (es) | Composición vacunal que comprende ipv y ciclodextrinas | |
| AR067471A1 (es) | Un componente de vacuna anti- pertussis y procedimiento simplificado para obtener pertactina ( prn ) de bordetella pertussis | |
| RU2014147491A (ru) | Антигены и антигенные композиции | |
| ES2224252T3 (es) | Composicion de vacuna que comprende fragmentos de la proteina de membrana externa de bordetella pertussis. | |
| Al-Jadiry | Childhood Immunization | |
| ZA202403479B (en) | Improved methods for poliovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| OA21991A (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof. | |
| AR097217A1 (es) | Composiciones inmunógenas de combinación |